Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure.
The single-dose (two 100 mg doses) pharmacokinetics of rimantadine hydrochloride were compared in eight patients with end-stage renal disease who were on hemodialysis and seven age-matched healthy subjects. Plasma and urine rimantadine concentrations were determined by a GC/MS method. The plasma half-life (43.6 vs 27.5 hours) and AUC (9.9 +/- 2.1 vs 6.0 +/- 1.6 micrograms.hr/ml) were significantly (p less than 0.05) increased in the patient population. No significant differences were noted in the maximum rimantadine concentration, time of maximum concentration, or apparent volume of distribution. Urinary excretion of unchanged rimantadine accounted for 16% of the dose in the healthy subjects. Hemodialysis did not appreciably remove rimantadine. These findings suggest that rimantadine dosage may need to be reduced in patients with end-stage renal disease but supplemental doses on dialysis days are not required.
Capparelli
E V
EV
Department of Pharmacy, Hartford Hospital, Conn.
Stevens
R C
RC
Chow
M S
MS
Izard
M
M
Wills
R J
RJ
D000218:Adamantane / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D006435:Renal Dialysis; D012299:Rimantadine / Q000008:administration & dosage / Q000493:pharmacokinetics*
D012299:Rimantadine; D000218:Adamantane